Efficacy and Safety of Briakinumab Versus Etanercept and Placebo in Patients with Moderate to Severe Chronic Plaque Psoriasis

Abstract

Background:  The anti-IL-12/23p40 monoclonal antibody briakinumab has been shown in a Phase 2 study to be effective psoriasis treatment.


Objective:  The aim of the current study was to assess the efficacy, safety, and tolerability of briakinumab compared with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.


Methods:  In this Phase III, 12-week study (M10-114, NCT00691964), 347 patients were randomised in a 2:2:1 ratio to receive 200 mg briakinumab at Weeks 0 and 4 followed by 100 mg briakinumab at Week 8 (n=138); 50 mg of etanercept twice weekly ...

Efficacy and Safety of Briakinumab Versus Etanercept and Placebo in Patients with Moderate to Severe Chronic Plaque Psoriasis is a post from: Skincare

Efficacy and Safety of Briakinumab Versus Etanercept and Placebo in Patients with Moderate to Severe Chronic Plaque Psoriasis via BuzzBlazer.com